MLTX (MoonLake Immunotherapeutics AG) Bathi resik

Simbol resmi perusahaan MoonLake Immunotherapeutics AG (MLTX)

Developing immune drugs involves immense scientific risks and pressure from industry behemoths. MoonLake Immunotherapeutics (MLTX) net income shows a turning point driven by the implementation of AI to accelerate molecular modeling amid the planned burn of cash reserves due to a lack of sales. The value of -0.27 reflects the latest metric value, capturing the issuer's current financial stability.

MLTX (MoonLake Immunotherapeutics) riwayat Bathi resik perusahaan saka 28.04.2023 nganti 31.10.2026

Rincian metrik komprehensif lan analitis MoonLake (MLTX)

- rega lan prakiraan konsensus rega:
Kutipan saham MoonLake Corp|MLTX - Prakiraan konsensus analis
- indikator valuasi pasar bisnis:
Kapitalisasi pasar MoonLake Corp|MLTX - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- data kapitalisasi buku:
Nilai Akuntansi Saham MoonLake Immunotherapeutics|MLTX - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih moonlaketx.com|MLTX - Total Aset Perusahaan
- informasi babagan utang lan solvabilitas:
Utang marang Modal MoonLake Immunotherapeutics|MLTX - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal MoonLake Immunotherapeutics AG|MLTX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku MoonLake Corp|MLTX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan MoonLake Immunotherapeutics|Likuiditas darurat moonlaketx.com
- indikator pendapatan resik lan kelipatan nilai:
MLTX - Bathi resik perusahaan
Pambiji fundamental:MoonLake Immunotherapeutics
Produk mawa merek moonlaketx.com

MoonLake Immunotherapeutics (MLTX) profit represents the final financial result reflecting the business's ability to generate net income after deducting all operating and tax obligations. By analyzing the MoonLake Immunotherapeutics (MLTX) profit chart, an investor can see the capitalization dynamics of MLTX, which currently depends critically on investments in the development of antibodies for the therapy of psoriasis and pyoderma gangrenosum until the drugs reach commercialization.

Pesaing langsung

Penghasilan resik Ascendis|MDGL (Madrigal Pharmaceuticals) - Bathi resik|Bathi resik corcept.com|Penghasilan resik RYTM (Rhythm Pharmaceuticals, Inc.)|AKRO (Akero Therapeutics, Inc.) - Bathi pungkasan|Bathi resik perusahaan Metsera Corp MTSR|CRNX - Penghasilan resik|NewAmsterdam Pharma - Bathi resik|Penghasilan resik perusahaan soleno.life|FOLD (Amicus Therapeutics, Inc.) - Penghasilan resik|ETNB: Bathi sawise mbayar pajeg|AGIO (Agios Pharmaceuticals Inc) - Bathi resik|Bathi resik Structure Corp|Bathi resik MDXG|Bathi resik perusahaan RZLT (rezolutebio.com)|Bathi resik perusahaan Lexicon Pharmaceuticals, Inc. LXRX|MBX Biosciences, Inc. (MBX) - Penghasilan resik perusahaan|ALT - Bathi resik perusahaan|AARD: Bathi resik perusahaan|SGMT: Bathi resik|BIOA - Asil keuangan resik|Bathi resik perusahaan Biomea Fusion|Quince (QNCX) - Asil keuangan resik|Bathi resik perusahaan Fractyl (GUTS)|Penghasilan resik vtvtherapeutics.com VTVT|Bathi resik perusahaan Agape ATP ATPC|PLUR - Penghasilan resik|SYBX - Bathi resik perusahaan|Penghasilan resik perusahaan Lipocine Inc|matinasbiopharma.com (MTNB) - Bathi resik perusahaan|Penghasilan resik perusahaan Spruce Biosciences Inc. (SPRB)|Bathi resik perusahaan Galecto, Inc.|Bathi perusahaan CTCX (carmellrx.com)|Bathi resik perusahaan Lumos Pharma (LUMO)|Bathi resik perusahaan ONVO (Organovo Holdings)|Bathi resik RDUS (Radius Health)